RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

In today's 10-Q it says the cash level at the end of March was approx $6000, so I must be missing something here. In Jan/Feb Drs. Lippa and Manuso advanced a total of $105 K in cash to the company, and that must have gone to pay Q1 expenses.

The Dronabinol trial is being fully paid by the NIH, but I can't figure out how they're paying for the recently started CX-1739 RD trial and the other company expenses. They're obviously paying for it somehow, so I must be missing something. They've done numerous 'Exchange Agreements' recently, which appear to swap older warrants for new, but not sure if the company gets any new cash as a result of these transactions.

It would be nice to get an update from the company. Perhaps additional info will be forthcoming in the next investor presentation Q+A.


http://www.sec.gov/Archives/edgar/data/849636/000149315216009771/form10-q.htm